Ocutears (Dextran 40 and Hypromellose) is commonly used as an ocular lubricant for symptomatic support in conditions presenting with localized discomfort. It is applied to help ease the symptoms associated with various types of ocular dryness and irritation, specifically to alleviate the sensations of burning and stinging.

The formulation may be part of symptomatic management in conditions presenting with episodic or fluctuating manifestations such as dry eye disease, and is used for managing sensory discomforts like burning, stinging, and the feeling of grittiness in the eye. It is applied in scenarios where additional management of discomfort is required, such as after extended digital screen use or exposure to environmental stressors. It assists with maintaining functional stability, providing symptomatic relief that may help patients cope more steadily with symptoms related to inflammatory or irritative states.

“It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Dryness and Irritation

The primary therapeutic benefit is to provide support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

1. NIH DailyMed Drug Facts Overview

Who Can and Cannot Use Ocutears

Official regulatory documents define the eligibility for Ocutears (Dextran and Hypromellose Ophthalmic Solution) based on population characteristics and known contraindications.

Contraindicated Populations

The primary and absolute restriction for using this medicine is a known hypersensitivity to dextran, hypromellose, or any of the excipients contained in the formulation. Patients with such allergies must not use the medicine.

---

Age and Physiological Eligibility

Population Group	Regulatory Status
Adults, Children, and the Elderly	Use is authorized and permitted for all age groups.
Pregnancy and Breastfeeding	Use can be used as negligible systemic absorption is anticipated, meaning adverse effects on the fetus or breastfed infant are not expected.
Renal or Hepatic Impairment	No restrictions are documented for the topical ocular formulation.

---

Eligibility Restrictions

Official labeling advises that caution should be exercised when the formulation contains preservatives and is used in patients with a severely compromised cornea.

The eligibility profile is characterized by a single, critical contraindication—hypersensitivity—while use is permitted across major age and reproductive status groups due to the localized, negligible systemic exposure of the ophthalmic solution.

Interactions with other medicines and products

Ocutears eye drops contain sodium hyaluronate, which is a lubricating agent that acts locally on the surface of the eye. Due to its mechanism of action and minimal systemic absorption, the product is generally not expected to interact with or affect the systemic pharmacokinetics of other orally taken or injectable medications.

Local Ophthalmic Interactions

The only known interaction context is with the local co-administration of other ocular medicinal products (e.g., other eye drops or ophthalmic ointments) in the same eye. This interaction is primarily physical and procedural.

Product Class	Interaction Type	Regulatory Constraint
Other Ophthalmic Medicines	Reduced Efficacy (via dilution)	Timing/Spacing Requirement

Procedural Constraint: To prevent the dilution and potential reduction in efficacy of any subsequently administered ocular medicine, a mandatory time interval must be observed. Official regulatory documents specify waiting for at least 5 to 10 minutes before applying any other medication in the same eye after Ocutears. Adhering to this spacing allows Ocutears to fully coat the eye surface without washing out the following treatment. It is recommended to apply lubricating products like Ocutears last, if possible, unless otherwise advised by a healthcare professional.

Ocutears is a high molecular weight hyaluronic acid (HA) polymer formulation. Its mechanism of action centers on its primary ingredient, the unique HA polymer. HA's action is based on its rheological properties and interaction with the tear film.

First, upon application to the ocular surface, the HA molecules instantly bind water molecules. This hygroscopic process generates a high viscosity solution, forming a viscoelastic layer that reduces mechanical friction between the eyelid and the cornea during blinking.

This molecular interaction contributes to the retention of the tear film's aqueous phase on the ocular surface. Second, the HA polymer interacts with the natural architecture of the ocular surface epithelium. By modulating the local microenvironment and the epithelial cell surface, HA polymers facilitate the maintenance of the ocular surface epithelium and its structural integrity.

Ocutears, an ophthalmic lubricating solution, is typically administered to relieve symptoms of dry eye and ocular discomfort by supplementing natural tears. The standard dosing involves applying 1 or 2 drops into each affected eye, one or more times a day, or as specifically advised by a healthcare professional.

Administration Steps

Step	Instruction
1. Preparation	Thoroughly wash your hands before handling the container to ensure hygiene and prevent contamination.
2. Application	Gently tilt your head back, pull down the lower eyelid to create a small pocket, and look upwards. Hold the dropper or container above the eye and gently squeeze to instill the recommended number of drops.
3. Avoid Contamination	Take care to ensure the tip of the container does not touch the eye, eyelid, or any other surface.
4. Post-Application	If using a multi-dose bottle, close the cap firmly immediately after use. Single-dose containers must be discarded after one use, even if residual solution remains.

Important Considerations

• Contact Lenses: Ocutears formulations are generally suitable for use while wearing contact lenses, but it's advisable to check the specific product leaflet or consult your doctor for guidance.
• Storage and Disposal: Store the product below 25 C (77 F) and protect it from heat and sunlight. Multi-dose bottles should be discarded 90 days after first opening, while single-dose containers must be discarded immediately after use.
• Other Eye Products: If you use other eye medications, you should wait at least 5 to 10 minutes between the administration of each product to avoid dilution.

Research evidence / Overview of studies for Ocutears

Evidence for Symptom Relief in Dry Eye Disease

Clinical research for ocular lubricants, including formulations within the class of tear substitutes like Ocutears (Dextran 40 and Hypromellose), has involved short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, specifically for adults experiencing mild to moderate dry eye symptoms. Researchers applied these studies examining patient-reported experiences related to burning, irritation, and overall ocular discomfort, often measured using standardized questionnaires.

The studies report how symptoms evolved in the observed populations, and findings describe patterns in patient-reported discomfort scores during the short observation periods (typically 4 weeks). Research also explored objective clinical outcomes, such as the stability of the tear film and signs of damage to the eye's surface, like corneal staining. Data indicate patterns related to these objective measures, but the findings were mixed, especially when studies evaluated this combination against other tear substitutes.

Research on Physical Properties and Ocular Surface Stability

Research has examined the physical mechanism of this combination, which is categorized as an ocular lubricant. Studies focused on viscosity and retention time on the eye's surface. The formulation was evaluated in laboratory settings and small clinical studies to monitor its ability to spread and stabilize the tear film after application.

Research describes that the presence of the combined polymers was associated with an increase in the measured viscosity of the solution compared to saline. Findings indicate that this higher viscosity was observed in some studies to contribute to a prolonged residence time of the solution on the ocular surface following a single application. These physical properties are outcomes related to systemic or functional imbalance and help contextualize how the product provides a layer of physical comfort.

Duration of Use and Long-term Follow-up

Because follow-up durations were limited, there is limited information for long-term outcomes regarding the maintenance of symptomatic relief or any sustained change in the underlying condition over a period of many months or years. Long-term effects are not fully established by the existing evidence base.

Evidence Gaps and Remaining Research Uncertainties

The evidence contributes to the broader evidence landscape for ocular lubricants, but certainty remains low regarding the performance relative to this specific Dextran/Hypromellose combination compared to the full array of newer tear substitute options now available. This variability across studies, coupled with the non-specific effects observed in dry eye research, limits the certainty about the unique contribution of the combined polymers.

Key Studies & References

1. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops
2. Submission for the 2023 Meeting of the WHO Expert Committee on Selection and Use of Essential Medicines (Hypromellose and Dry Eye Disease)
3. Dextran - StatPearls [Used to understand Dextran 40 general properties]

Common questions about Ocutears (FAQ)

---

Q: Is Ocutears the same thing as artificial tears?

Official classifications describe Ocutears as an ocular lubricant and a tear substitute. These terms are used interchangeably with the common phrase "artificial tears" to describe non-pharmacological solutions that help support the eye's natural tear film.

---

Q: Does Ocutears contain preservatives?

According to the official product labeling, Ocutears formulations are explicitly stated to be preservative-free.

---

Q: Why is Ocutears sometimes recommended over a saline solution?

The formulation of Ocutears is claimed to provide unique viscoelastic properties, which allow it to form a more stable and longer-lasting film on the surface of the eye. This stabilizing film contributes to reduced mechanical friction and is intended to support prolonged comfort, which is a feature not shared by simple saline solutions.

---

Q: Is Ocutears safe to use with all types of contact lenses?

Official product information states that Ocutears is suitable for use by contact lens wearers. It can be applied directly to the eye without the need to remove your lenses beforehand.

---

Q: Is Ocutears considered a medicine or a medical device in some regions?

Ocutears is often regulated and marketed as a Medical Device in certain jurisdictions, as indicated by markings such as the CE mark in the EU. This classification reflects its primary mechanism of action, which is physical lubrication rather than a chemical or pharmacological effect on the body.

---

Q: Is Ocutears plant-based or chemically synthesized?

The active components are officially described as semisynthetic polymers. This means they are chemically modified from materials that originated from natural sources, such as derivatives of cellulose or polysaccharides.

---

Q: Does the feeling of Ocutears in the eye change over time?

The product is formulated with high viscoelasticity to ensure greater permanence on the ocular surface after application. This property is intended to contribute to prolonged relief and support the tear film.

---

Q: Is there a maximum amount of Ocutears that can be used daily?

Official instructions for use state to apply the drops one or more times a day or as directed by a healthcare professional. General guidance does not specify a maximum daily drop count, allowing for flexible use as needed.

---

Q: How long do the effects of Ocutears typically last?

The product is labeled and formulated to offer prolonged hydration and comfort. The product's physical mechanism is specifically designed to prolong the retention of the lubricating film on the ocular surface.

---

Q: What should I do if I miss a scheduled use of Ocutears?

Since Ocutears is a lubricating drop, it is used on an as-needed (p.r.n.) basis to relieve symptoms of discomfort. Therefore, there is no formal "missed dose" protocol. The product may be applied when ocular dryness or irritation occurs.

---

Q: What if I accidentally put more Ocutears drops in my eye than intended?

As the product is a lubricant with a non-pharmacological action and negligible systemic absorption, no adverse effects are anticipated from local over-administration. Any excess solution would be naturally washed away by tears.

---

Q: Does Ocutears have different versions or strengths?

Yes, the Ocutears product line includes different versions, such as Ocutears Hydro+ and Ocutears Alo+, which are formulated with varying components to address specific dry eye symptoms or patient needs.

---

Q: Has Ocutears been approved by the FDA or a similar major regulatory body?

The product is registered and compliant in many jurisdictions, demonstrated by regulatory markings such as the CE mark in the European Union. These markings indicate that the product meets the necessary safety and performance requirements for market authorization in that jurisdiction.

---

Q: What happens if I forget to store Ocutears at the recommended temperature?

Official storage guidance requires the product be stored below 25^\circC (77^\circF). If the product is exposed to temperatures outside of this range for a prolonged time, its stability and lubricating properties may be compromised. Disposal according to official instructions is recommended.

---

Q: Does the time of day matter when using Ocutears?

The official instructions for use state that Ocutears can be applied one or more times a day. This indicates that the product can be used whenever needed to relieve discomfort, without restriction to a specific time of day.

---

Q: What are the key inactive ingredients in Ocutears?

The full list of inactive ingredients, or excipients, is provided on the official product label. Key inactive components often include Boric acid, Sodium chloride, and Water for injections (WFI), which are included to maintain the solution's sterility and balance.

---

Q: Why do some people experience watery eyes after using Ocutears?

Watery eyes, or excessive tearing, is a local reaction that may occur in some individuals. This is a documented adverse event for this class of product and is listed in post-marketing safety data.

---

Q: Can I share my Ocutears with another person?

Ocutears eye drops are strictly intended for personal use only. Official guidelines state that sharing is not recommended due to the risk of transferring infection or potential cross-contamination.

---

Q: How quickly should I expect to notice the effects of Ocutears?

Due to the physical properties of the solution coating the eye surface, Ocutears is designed to offer immediate lubrication and comfort upon application.

---

Q: Can I use Ocutears if I have had eye surgery recently?

Official product labeling for certain versions, such as Ocutears Hydro+, specifically states that the product may be used to help relieve post-surgery discomfort of the eye.

---

Q: Can Ocutears be used for purposes other than the main use described?

The product is indicated only for its official uses, which include the relief of dry eye symptoms, ocular discomfort, and corneal protection. Use outside of these official indications is not covered by the product labeling.

---

Q: What if Ocutears seems to make my symptoms worse initially?

Official instructions state that if eye irritation or other symptoms persist or worsen during use, it is recommended to discontinue the product and seek guidance from a healthcare professional.

---

Q: Does Ocutears help with symptoms related to screen use?

Yes, the product is specifically indicated for symptoms caused by various factors, including environmental conditions and extended activities such as prolonged screen use.

---

Q: What is the typical shelf life of an unopened Ocutears package?

The product is assigned an expiration date (EXP), which is based on stability data for the unopened package and is located on the packaging.

---

Q: Why do I need to shake some eye drops but not Ocutears?

Ocutears is a homogeneous solution, meaning the ingredients are uniformly mixed. Products that require shaking are typically non-homogenous suspensions or emulsions that need to be mixed prior to use, which is not necessary for this formulation.

---

Q: Is the main component in Ocutears naturally occurring in the eye?

The active component, sodium hyaluronate (HA), is officially described as a moisturizer that is naturally found in the body. This substance is similar to components already present in the tear film.

Ocutears ophthalmic solution must be stored according to official regulatory requirements to ensure its stability and sterility.

Storage Conditions

Temperature: The product must be stored below 25 C (77 F) and must not be frozen.

Protection: Store the medicine away from heat, direct sunlight, and moisture.

Child Safety: It is mandatory to keep the product out of the sight and reach of children.

Handling and Stability

Multi-dose containers must be closed firmly after use and typically discarded within 30 to 90 days after first opening. Single-dose containers must be used immediately after opening and any remaining solution must be discarded to maintain sterility.

Disposal

Unused or expired Ocutears must be disposed of according to local regulatory requirements and should not be discarded via household wastewater or general trash.